New Current Report Filed with the SEC Disclosing Receipt of a Notice of Delisting, the Failure to Satisfy a Continued Listing Rule or Standard or the Transfer of a Listing: 8-K – Anthera Pharmaceuticals Inc (0001316175) (Filer)

A current report on Form 8-K was just filed with the U.S. Securities & Exchange Commission (SEC) disclosing receipt of a notice of delisting, the failure to satisfy a continued listing rule or standard or the transfer of a listing. Details of the current report are:

8-K – Anthera Pharmaceuticals Inc (0001316175) (Filer)
Filed: 2017-02-16 AccNo: 0001214659-17-001208 Size: 17 KB

Item 3.01: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing
Filing Date: 2017-02-16T16:45:22-05:00

This is a breaking news story. You can access the complete current report through the SEC’s Edgar system: http://www.sec.gov/Archives/edgar/data/1316175/000121465917001208/0001214659-17-001208-index.htm